NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
The ANDA was filed as 'First to File' submission on NCE-1 date.
Apollo Pharmacy has over 50% market share amongst India’s organized pharmacies
The campaign will also focus on providing doorstep TB screening services to facilitate diagnosis
MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Subscribe To Our Newsletter & Stay Updated
